PRERAS: Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM.

Sponsor
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (Other)
Overall Status
Unknown status
CT.gov ID
NCT03618329
Collaborator
(none)
130
2
14.9

Study Details

Study Description

Brief Summary

The implementation of prehabilitation in patients operated on for colon cancer in a multimodal rehabilitation regimen improves the values of the "lean body mass" or lean mass index, positively influencing the results of clinical, analytical and radiological nutritional values pre- and postoperatively and in morbi-mortality, recovery, average stay and re-entry rates.

Condition or Disease Intervention/Treatment Phase
  • Other: Prehabilitation
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
130 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Effect of Prehabilitation on the Lean Mass Index (IMM) in Patients Operated on for Colon Cancer in ERAS Programm.
Anticipated Study Start Date :
Oct 1, 2018
Anticipated Primary Completion Date :
Jun 30, 2019
Anticipated Study Completion Date :
Dec 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Prehabilitation

exercise, nutrition and anxiety reduction in the preoperative period

Other: Prehabilitation
exercise, nutrition and anxiety reduction in the preoperative period

No Intervention: No Prehabilitation

Not: exercise, nutrition and anxiety reduction in the preoperative period

Outcome Measures

Primary Outcome Measures

  1. Effect of prehabilitation on the change from lean mass index [preoperative and 1-month postoperative]

    Effect of prehabilitation on the lean mass index

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • It is considered that the subject suffers a confirmed diagnosis of colon cancer and is going to undergo surgery on a scheduled basis under a RHMM program.

  • The subject is ≥ 18 years of age.

  • The subject can perform any of the two proposed treatments.

  • Preoperative staging TxNxM0.

  • The patient has voluntarily signed and dated an informed consent document (IC), approved by an independent Ethics Committee (CEIC) before participating in the study.

Exclusion Criteria:
  • Patients with rectal cancer.

  • The study doctor determines that the subject is not eligible to participate.

  • The subject can not give informed consent to participate in the study.

  • The subject can not perform the pre-habilitation.

  • Non-acceptance or impossibility of following rehabilitation protocol multimodal

  • The subject was previously scheduled at the time of the inclusion of the nutritional supplement study, whether it is different or the same that would be scheduled at this time

  • Subjects who have received previous radiochemotherapy, HIV, gestational stage, psychiatric, with CRF who are undergoing renal replacement techniques, urgent surgery, with intestinal obstructions, with uncontrolled infections, urgent surgery, distant metastasis, ASA IV, advanced liver failure, severe coagulation disorder, severe hyperlipidemia and hyperglycemia or difficult to control.

  • Subject has renal or hepatic impairment (GFR <60ml / m or AST / ALT 3 x upper limit of normal).

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Antonio Arroyo Sebastian, Prof, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
ClinicalTrials.gov Identifier:
NCT03618329
Other Study ID Numbers:
  • PRERAS
First Posted:
Aug 7, 2018
Last Update Posted:
Aug 7, 2018
Last Verified:
Aug 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Antonio Arroyo Sebastian, Prof, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 7, 2018